Percheron Therapeutics Limited

DB:AWY0 Stock Report

Market Cap: €5.8m

Percheron Therapeutics Valuation

Is AWY0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AWY0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AWY0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AWY0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AWY0?

Key metric: As AWY0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AWY0. This is calculated by dividing AWY0's market cap by their current revenue.
What is AWY0's PS Ratio?
PS Ratio3.2x
SalesAU$2.97m
Market CapAU$9.54m

Price to Sales Ratio vs Peers

How does AWY0's PS Ratio compare to its peers?

The above table shows the PS ratio for AWY0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.1x
0K30 TFF Pharmaceuticals
8.6xn/a€9.7m
B8FK Biofrontera
0.7xn/a€13.5m
SBX SynBiotic
5.7x39.8%€22.0m
0RX Redx Pharma
13.3x-37.6%€65.0m
AWY0 Percheron Therapeutics
3.2x42.1%€9.5m

Price-To-Sales vs Peers: AWY0 is good value based on its Price-To-Sales Ratio (3.2x) compared to the peer average (7.1x).

Price to Sales Ratio vs Industry

How does AWY0's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

18 CompaniesPrice / SalesEstimated GrowthMarket Cap
AWY0 3.2xIndustry Avg. 3.0xNo. of Companies21PS048121620+
18 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AWY0 is expensive based on its Price-To-Sales Ratio (3.2x) compared to the European Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is AWY0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AWY0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.2x
Fair PS Ratio85.7x

Price-To-Sales vs Fair Ratio: AWY0 is good value based on its Price-To-Sales Ratio (3.2x) compared to the estimated Fair Price-To-Sales Ratio (85.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AWY0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.0045
€0.054
+1,101.6%
125.7%€0.15€0.006n/a3
Dec ’25€0.041
€0.13
+220.7%
23.7%€0.15€0.087n/a3
Nov ’25€0.042
€0.13
+217.5%
25.7%€0.17€0.086n/a3
Oct ’25€0.058
€0.13
+130.4%
25.7%€0.17€0.086n/a3
Sep ’25€0.048
€0.13
+179.4%
25.7%€0.17€0.086n/a3
Aug ’25€0.037
€0.13
+259.7%
25.5%€0.17€0.087n/a3
Jul ’25€0.044
€0.15
+249.2%
8.0%€0.17€0.14n/a2
Jun ’25€0.04
€0.15
+283.3%
8.0%€0.17€0.14n/a2
May ’25€0.036
€0.15
+315.3%
8.0%€0.16€0.14n/a2
Apr ’25€0.046
€0.15
+231.5%
8.0%€0.16€0.14n/a2
Mar ’25€0.046
€0.15
+225.8%
8.0%€0.16€0.14n/a2
Feb ’25€0.031
€0.15
+386.1%
8.0%€0.16€0.14n/a2
Jan ’25€0.031
€0.16
+416.8%
13.2%€0.18€0.14€0.00452
Dec ’24€0.031
€0.16
+416.8%
13.2%€0.18€0.14€0.0412
Nov ’24€0.03
€0.16
+437.7%
13.2%€0.18€0.14€0.0422
Oct ’24€0.039
€0.16
+304.0%
13.2%€0.18€0.14€0.0582
Sep ’24€0.033
€0.16
+383.3%
13.2%€0.18€0.14€0.0482
Aug ’24€0.029
€0.17
+492.2%
7.1%€0.18€0.16€0.0372
Jul ’24€0.036
€0.19
+427.3%
16.1%€0.22€0.16€0.0442
Jun ’24€0.035
€0.19
+439.6%
16.1%€0.22€0.16€0.042
May ’24€0.045
€0.20
+350.4%
16.1%€0.23€0.17€0.0362
Apr ’24€0.051
€0.20
+296.4%
16.1%€0.23€0.17€0.0462
Mar ’24€0.059
€0.20
+244.3%
16.1%€0.23€0.17€0.0462
Feb ’24€0.055
€0.20
+260.5%
16.1%€0.23€0.17€0.0312
Jan ’24€0.056
€0.21
+272.5%
16.1%€0.24€0.18€0.0312

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 06:09
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Percheron Therapeutics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Iain WilkieMorgans Financial Limited
Dr StoreyWilsons Advisory and Stockbroking Ltd.